Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06814587 · ClinicalTrials.gov registry record

Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy

A clinical trial of Coronary Artery Disease and Coronary Artery Bypass Graft (CABG), sponsored by University of Texas Southwestern Medical Center.

Recruiting
Registry status
15
Enrollment target
1
Study location

NCT06814587: Recruiting study of Coronary Artery Disease and Coronary Artery Bypass Graft (CABG), sponsored by University of Texas Southwestern Medical Center.

NCT06814587 is a study of Coronary Artery Disease and Coronary Artery Bypass Graft (CABG) that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 15 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06814587, a study of Coronary Artery Disease and Coronary Artery Bypass Graft (CABG), is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.

RECRUITING
Registry status
15 participants
Enrollment target
1
Study location

Study Summary

This prospective, non-blinded, single-center, translational research study aims to validate a multimodal advanced imaging exam for cardiac viability. The protocol utilizes three distinct imaging modalities: Single Photon Emission Computed Tomography Myocardial Perfusion Imaging (SPECT MPI), 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), and Hyperpolarized Carbon-13 (HP-13C) Pyruvate Magnetic Resonance Imaging (MRI). Under this protocol, the SPECT MPI and FDG-PET exams will be used in combination to comprehensively assess myocardial viability. Concurrently, the HP-13C Pyruvate MRI will be utilized to provide additional insights into myocardial metabolism. The study will evaluate healthy volunteers to establish baseline parameters and patients with ischemic cardiomyopathy (ICM) before and after surgical revascularization.

Primary Outcome

This outcome evaluates the ability of hyperpolarized 13C pyruvate MRI (HP-13C MRI) to assess myocardial metabolism, alongside myocardial viability assessment using FDG-PET and SPECT MPI, in patients with ischemic cardiomyopathy compared with healthy subjects. Quantitative assessment with HP-13C MRI will focus on the metabolic conversion of pyruvate to intermediates like bicarbonate and lactate as a marker of oxidative versus anaerobic metabolism. These results will be compared with regional FDG

Conditions Studied

Coronary Artery Disease Coronary Artery Bypass Graft (CABG)

Interventions

  • DIAGNOSTIC_TEST Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI)
  • DIAGNOSTIC_TEST [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
  • DIAGNOSTIC_TEST SPECT MPI (Single Photon Emission Computed Tomography Myocardial Perfusion Imaging)

Study Locations (1)

Texas

  • University of Texas Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2024-07-01
Est. Completion 2026-06-30
University of Texas Southwestern Medical Center

837 total trials

What NCT06814587 shows while recruiting

NCT06814587 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 3 interventions - of which Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI) is the first listed.

NCT06814587 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06814587 about?

NCT06814587 is a clinical study titled "Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy". This prospective, non-blinded, single-center, translational research study aims to validate a multimodal advanced imaging exam for cardiac viability. The protocol utilizes three distinct imaging modalities: Single Photon Emission Computed Tomography Myocardial Perfusion Imaging (SPECT MPI), 18F-fluo...

What is the current status of trial NCT06814587?

This trial is currently recruiting. The enrollment target is 15 participants. The study started on 2024-07-01. Estimated completion is 2026-06-30.

What conditions does trial NCT06814587 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Coronary Artery Bypass Graft (CABG).

What interventions are being tested in trial NCT06814587?

The interventions under investigation include: Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI) (DIAGNOSTIC_TEST), [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) (DIAGNOSTIC_TEST), SPECT MPI (Single Photon Emission Computed Tomography Myocardial Perfusion Imaging) (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06814587?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06814587 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06814587's enrollment target sits among peer trials

15 214th of 219 higher than 6 of 219 other Coronary Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06814587

Source: ClinicalTrials.gov NCT06814587, the US trial registry maintained by the National Library of Medicine. NCT06814587 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.